Top Markets
#1 DogBull DogBull +107.71%
#2 MarsCoin MarsCoin +63.63%
#3 ADO Protocol ADO Protocol +52.07%
#4 Siacoin Siacoin +42.87%
#5 Ontology Gas Ontology Gas +24.40%
#6 The Bitcoin Bull The Bitcoin Bull +17.58%
#7 Apertum Apertum +15.01%
#8 Useless Coin Useless Coin +13.70%
#9 UnifAI Network UnifAI Network +12.09%
#10 Nockchain Nockchain +11.09%
Coin of the day
DogBull DogBull
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Rang in aandelen #15114
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Aandeelprijs
$4.74
Laatst gesynchroniseerd: 2026-08-31
Marktkapitalisatie
$372.19M
Verandering (1 dag)
-2.47%
Verandering (1 jaar)
-1.04%
Land
US
Handel Lexeo Therapeutics, Inc. Common Stock (LXEO)

Categorie

Healthcare
Winst voor Lexeo Therapeutics, Inc. Common Stock (LXEO)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Lexeo Therapeutics, Inc. Common Stock bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Lexeo Therapeutics, Inc. Common Stock van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH